Cantor Fitzgerald reaffirmed their buy rating on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in a report published on Monday morning. The brokerage currently has a $8.00 price objective on the specialty pharmaceutical company’s stock.
“One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming.”,” the firm’s analyst wrote.
AGRX has been the topic of a number of other reports. Janney Montgomery Scott reaffirmed a buy rating and set a $15.00 price target on shares of Agile Therapeutics in a research note on Friday, July 21st. Royal Bank Of Canada reaffirmed a buy rating and set a $10.00 price target on shares of Agile Therapeutics in a research note on Wednesday, October 18th. HC Wainwright reaffirmed a buy rating and set a $10.00 price target on shares of Agile Therapeutics in a research note on Monday, October 2nd. ValuEngine cut shares of Agile Therapeutics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Finally, Noble Financial reaffirmed a buy rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Agile Therapeutics presently has a consensus rating of Buy and a consensus price target of $10.20.
Agile Therapeutics (AGRX) traded up $0.04 during trading hours on Monday, hitting $4.55. 14,050 shares of the stock were exchanged, compared to its average volume of 374,421. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.37 and a current ratio of 4.10. Agile Therapeutics has a fifty-two week low of $1.82 and a fifty-two week high of $7.39.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.03. equities research analysts expect that Agile Therapeutics will post -1.01 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by BBNS and is the property of of BBNS. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://baseballnewssource.com/markets/agile-therapeutics-inc-agrx-rating-reiterated-by-cantor-fitzgerald/1762416.html.
In other Agile Therapeutics news, Chairman Alfred Altomari acquired 10,000 shares of the stock in a transaction that occurred on Friday, August 25th. The shares were purchased at an average cost of $3.34 per share, with a total value of $33,400.00. Following the purchase, the chairman now owns 161,587 shares in the company, valued at $539,700.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of AGRX. Franklin Resources Inc. grew its stake in Agile Therapeutics by 39.2% in the 2nd quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after acquiring an additional 780,578 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Agile Therapeutics in the 3rd quarter valued at about $943,000. JPMorgan Chase & Co. acquired a new stake in Agile Therapeutics in the 3rd quarter valued at about $467,000. Goldman Sachs Group Inc. acquired a new stake in Agile Therapeutics in the 2nd quarter valued at about $309,000. Finally, Dimensional Fund Advisors LP grew its stake in Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after acquiring an additional 82,213 shares during the last quarter. 67.52% of the stock is currently owned by hedge funds and other institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with our FREE daily email newsletter.